Elanco Animal Health Incorporated (ELAN) Stock Profile & Financial OverviewElanco Animal Health Incorporated
ELAN Company Overview & Business Description
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Key Information
Current Trend for ELAN
An assessment of the current trend environment for ELAN, based on the latest closing price data and intended to describe the market context heading into the next trading session.
As of 2025-12-24, the current trend for ELAN is a Sideways Consolidation (Range-Bound Environment).
The weekly trend is in a consolidation regime, which automatically downgrades the daily signal to sideways conditions. This environment favors short-term mean-reversion rather than trend-following.
- The weekly context is non-trending (sideways), which typically caps the duration and magnitude of daily trend moves.
- Price is currently trending at a healthy distance, sitting 0.80 ATR away from the adaptive KAMA baseline.
- The current market structure is holding within recent defined ranges.
Explore More Data
Adaptive Trend Model · Daily & Weekly (2025-12-24 ET)
This model uses an adaptive trend algorithm based on daily and weekly price data to identify whether a stock is in an uptrend, downtrend, or consolidation over a multi-week to multi-month horizon. Compared with traditional moving-average systems, it filters short-term noise more effectively, captures trend continuation more reliably, and provides a stronger basis for position sizing and risk-management decisions such as stop-loss and take-profit levels.
As of 2025-12-24, ELAN in an emerging upward cycle; Long-term trend is bullish.
Trend Strength: ELAN last closed at 22.38, trading 0.9 ATR above the adaptive KAMA baseline (21.82). Technical Classification: Early-Stage / Emerging Trend.
Trend Score: Technical Score: 80/100. Classification: Early/Developing. Alignment: High. Logic: Full multi-timeframe alignment with strong momentum filters.
SuperTrend Risk: Structural Support: Adaptive SuperTrend at 20.27. This level serves as the calculated invalidation point for the current upward structure.
Risk Skew: Multi-timeframe risk skew is currently assessed as Upside-Biased. The bullish bias remains intact, supported by multi-timeframe alignment, though momentum is in a maturing stage.
Key Levels: In this bullish structure, key support is anchored by immediate support (KAMA) at 21.82, with the critical trend-guard (SuperTrend) at 20.27.